Answers are grounded in this paper and cite their sources.
In patients with treatment-resistant depression, esketamine nasal spray plus an SSRI or SNRI was superior to extended-release quetiapine plus an SSRI or SNRI with respect to remission at week 8. (Funded by Janssen EMEA; ESCAPE-TRD ClinicalTrials.gov number, NCT04338321.).
No takes yet. Share an insight, caveat, or question.
Reif et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: